Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

REC-1245

Small molecule (Molecular glue degrader) · Degrader of RNA-binding motif protein 39 (RBM39) · developed by Recursion Pharmaceuticals

Phase 1/2 Most advanced trial
RXRX Developer
1 Registered trials

What is REC-1245?

REC-1245 is an orally bioavailable molecular glue degrader that targets the splicing factor RBM39. It recruits RBM39 to the E3 ligase adaptor DCAF15, promoting its ubiquitination and proteasome-mediated degradation, which alters RNA splicing and downregulates DNA damage response networks. It is being studied in unresectable, locally advanced or metastatic cancers and relapsed or refractory lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule (Molecular glue degrader)
Targets
RNA-binding motif protein 39 (RBM39), DCAF15 (binding partner it blocks)
Mechanism
Degrader of RNA-binding motif protein 39 (RBM39)
Pathways
RNA splicing, DNA damage response, cell cycle checkpoint control, ubiquitin-proteasome degradation
Therapy area
Oncology
Developer
Recursion Pharmaceuticals Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06678659 Phase 1/2 Unresectable Recruiting RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally AdvancedMetastatic CancersRelapsed/Refractory LymphomasUnresectable

More from Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind REC-1245

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.